AVTX vs C · P/E 0.0, rev $441.0K vs P/E 16, rev $85.22B
Avalo Therapeutics Inc (AVTX) versus Citigroup Inc. (C) — a side-by-side from cached financials, not a winner call.
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Latest reported AVTX revenue for 2024-12-31 was $441.0K. Net income was -$35.1M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. C currently screens at market cap $214.73B and trailing P/E 15.5.
Not investment advice. Open the AVTX and C stock pages for the full models.
Not investment advice.